2026-07-06 | Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics | NDAQ:MOLN | Press Release
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) updated its targeted alpha Radio-DARPin pipeline. MP0712 (212Pb, DLL3) dosing is ongoing in a US Phase 1/2a study; initial data expected in coming months and more complete safety/efficacy in 2027. MP0726 (MSLN) imaging planned H2 2026; two INDs planned in 2027.
How this was made
The 30-second read
Why it matters
The update advances MP0712 through Phase 1 initiation and ongoing dosing, while outlining next milestones (MP0726 first-in-human imaging in H2 2026; additional INDs and target nomination in 2027).
Market read
Traders can monitor the next months for the first MP0712 clinical data window and use the stated H2 2026/2027 milestones to frame longer-dated expectations.
What to watch
Key risk is clinical readout quality (safety tolerability, biodistribution, tumor uptake) and operational execution across cohorts/centers; isotope supply and partner execution (Orano Med, PanTera, Eckert & Ziegler) could also affect timelines.
Background
Molecular Partners is advancing a pipeline of targeted alpha Radio-DARPins, using DARPins as isotope-agnostic vectors for different alpha-emitting payloads.
Ticker impact
Molecular Partners reports Phase 1/2a dosing is ongoing for MP0712 (212Pb, DLL3) with initial data expected within months and broader dataset in 2027.
Moderate upside bias into the next months as investors price the first MP0712 readout; volatility likely around trial-data timing and any updates to cohort progression.
The release is a primary clinical-development update (ongoing dosing, data timing) rather than a recap, but it does not provide new efficacy/safety results or guidance numbers that would typically drive a large repricing today.
Market effects
Reinforces investor narrative that isotope-agnostic DARPin vectors can flex across alpha payloads (212Pb/225Ac/177Lu/203Pb), potentially improving platform valuation for targeted alpha peers.
US trial execution (multicenter Phase 1/2a) and Switzerland/US corporate base keep attention on US clinical timelines.
South Africa compassionate-care work and planned H2 2026 imaging highlight global development momentum and isotope supply-chain relevance (e.g., 225Ac).
Counterpoint
Because the release provides no new efficacy/safety results—only dosing status and expected data windows—market reaction may fade if investors already anticipated similar timelines.
Key entities
- companyMolecular Partners AG
Clinical-stage biotech developing DARPin therapeutics; subject of the press release and provider of MP0712/MP0726 pipeline updates.
- programMP0712
DLL3-targeted Radio-DARPin carrying 212Pb; US multicenter Phase 1/2a dosing ongoing with initial data expected within months.
- programMP0726
MSLN-targeted Radio-DARPin; planned to start first-in-human imaging in H2 2026.
- partnerOrano Med
Co-developer/strategic partner for MP0712 (212Pb-based targeted alpha therapy).
